Skip to main content
. 2017 Jan 3;8(7):11990–12002. doi: 10.18632/oncotarget.14467

Figure 6. Inhibition of VEGFR2 by Apatinib decreased cell proliferation by blocking VEGFR2-PLCγ1-ERK1/2 pathway and reduced VEGF secretion.

Figure 6

A. The viability of gastric cancer cells in response to Apatinib in SGC-7901 (left panel), BGC-823 (middle panel), and MGC-803 cells (right panel). B. Treating with Apatinib, proliferation of gastric cancer cell lines in response to rhVEGF in SGC-7901 (left panel), BGC-823 (middle panel), and MGC-803 cells (right panel). C. Treating cells with Apatinib at different concentration affected secretion of VEGF in SGC-7901 (left panel), BGC-823 (middle panel), and MGC-803 cells (right panel). D. The protein levels were measured by Western blot after treating cells with Apatinib. GAPDH was included as a loading control. Mean±SEM, t-test, *P<0.05, **P<0.01, ***P<0.001.